{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:00:18Z","timestamp":1780102818681,"version":"3.54.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Biohaven, Pfizer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02290-6","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:41:34Z","timestamp":1772206894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study"],"prefix":"10.1186","volume":"27","author":[{"given":"Yasuhiko","family":"Matsumori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigekazu","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0901-368X","authenticated-orcid":false,"given":"Tomofumi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yoshimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Thiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Fullerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2290_CR1","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1\u2013211). https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"2290_CR2","doi-asserted-by":"publisher","first-page":"333102424127434","DOI":"10.1177\/03331024241274343","volume":"44","author":"Z Katsarava","year":"2024","unstructured":"Katsarava Z, Buse DC, Leroux E et al (2024) Disability in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) study. Cephalalgia 44:3331024241274343. https:\/\/doi.org\/10.1177\/03331024241274343","journal-title":"Cephalalgia"},{"key":"2290_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain"},{"key":"2290_CR4","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/j.1526-4610.2005.00259.x","volume":"45","author":"F Nachit-Ouinekh","year":"2005","unstructured":"Nachit-Ouinekh F, Dartigues JF, Chrysostome V et al (2005) Evolution of migraine after a 10-year follow-up. Headache 45:1280\u20131287. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.00259.x","journal-title":"Headache"},{"key":"2290_CR5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1212\/01.wnl.0000172918.74999.8a","volume":"65","author":"AC Lyngberg","year":"2005","unstructured":"Lyngberg AC, Rasmussen BK, J\u00f8rgensen T, Jensen R (2005) Prognosis of migraine and tension-type headache: a population-based follow-up study. Neurology 65:580\u2013585. https:\/\/doi.org\/10.1212\/01.wnl.0000172918.74999.8a","journal-title":"Neurology"},{"key":"2290_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/WCO.0b013e328300c6f5","volume":"21","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Lipton RB (2008) The prognosis of migraine. Curr Opin Neurol 21:301\u2013308. https:\/\/doi.org\/10.1097\/WCO.0b013e328300c6f5","journal-title":"Curr Opin Neurol"},{"key":"2290_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-023-01619-9","volume":"24","author":"L Fan","year":"2023","unstructured":"Fan L, Wu Y, Wei J et al (2023) Global, regional, and national time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019. J Headache Pain 24:79. https:\/\/doi.org\/10.1186\/s10194-023-01619-9","journal-title":"J Headache Pain"},{"key":"2290_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40120-023-00438-z","volume":"12","author":"E Bentivegna","year":"2023","unstructured":"Bentivegna E, Onan D, Martelletti P (2023) Unmet needs in preventive treatment of migraine. Neurol Ther 12:337\u2013342. https:\/\/doi.org\/10.1007\/s40120-023-00438-z","journal-title":"Neurol Ther"},{"key":"2290_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-024-01722-5","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Kitano T, Iijima M, Togo K, Yonemoto N (2024) Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan. J Headache Pain 25:19. https:\/\/doi.org\/10.1186\/s10194-024-01722-5","journal-title":"J Headache Pain"},{"key":"2290_CR10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021\u20131039. https:\/\/doi.org\/10.1111\/head.14153","journal-title":"Headache"},{"key":"2290_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17:501\u2013514. https:\/\/doi.org\/10.1038\/s41582-021-00509-5","journal-title":"Nat Rev Neurol"},{"key":"2290_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-019-1012-1","volume":"20","author":"K Ueda","year":"2019","unstructured":"Ueda K, Ye W, Lombard L et al (2019) Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain 20:68. https:\/\/doi.org\/10.1186\/s10194-019-1012-1","journal-title":"J Headache Pain"},{"key":"2290_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second International Burden of Migraine Study (IBMS-II). Headache 53:644\u2013655. https:\/\/doi.org\/10.1111\/head.12055","journal-title":"Headache"},{"key":"2290_CR14","volume-title":"Clinical practice guideline for headache disorders 2021","author":"Headache Clinical Practice Guideline Development Committee","year":"2021","unstructured":"Headache Clinical Practice Guideline Development Committee (2021) Clinical practice guideline for headache disorders 2021. Igaku-Shoin, Tokyo"},{"key":"2290_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10194-023-01539-8","volume":"24","author":"L Al-Hassany","year":"2023","unstructured":"Al-Hassany L, Lyons HS, Boucherie DM et al (2023) The sense of stopping migraine prophylaxis. J Headache Pain 24:9. https:\/\/doi.org\/10.1186\/s10194-023-01539-8","journal-title":"J Headache Pain"},{"key":"2290_CR16","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s40120-024-00663-0","volume":"13","author":"T Takeshima","year":"2024","unstructured":"Takeshima T, Yuasa A, Lloyd YM et al (2024) A discrete-choice experiment assessing the patient preferences and real-world experiences of patients with migraine in Japan. Neurol Ther 13:1661\u20131683. https:\/\/doi.org\/10.1007\/s40120-024-00663-0","journal-title":"Neurol Ther"},{"key":"2290_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG et al (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381:142\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1811090","journal-title":"N Engl J Med"},{"key":"2290_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394:737\u2013745. https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X","journal-title":"Lancet"},{"key":"2290_CR19","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2147\/jpr.S453806","volume":"17","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Thiry A, Morris BA, Croop R (2024) Efficacy and safety of rimegepant 75 mg oral tablet, a CGRP receptor antagonist, for the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. J Pain Res 17:2431\u20132441. https:\/\/doi.org\/10.2147\/jpr.S453806","journal-title":"J Pain Res"},{"key":"2290_CR20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1474-4422(23)00126-6","volume":"22","author":"S Yu","year":"2023","unstructured":"Yu S, Kim BK, Guo A et al (2023) Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 22:476\u2013484. https:\/\/doi.org\/10.1016\/S1474-4422(23)00126-6","journal-title":"Lancet Neurol"},{"key":"2290_CR21","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1111\/head.14994","volume":"65","author":"K Ikeda","year":"2025","unstructured":"Ikeda K, Matsumori Y, Kudo M et al (2025) Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: a dose-ranging, double-blind, randomized controlled trial. Headache 65:1811\u20131820. https:\/\/doi.org\/10.1111\/head.14994","journal-title":"Headache"},{"key":"2290_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397:51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)32544-7","journal-title":"Lancet"},{"key":"2290_CR23","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/head.14995","volume":"65","author":"S Kitamura","year":"2025","unstructured":"Kitamura S, Matsumori Y, Yamamoto T et al (2025) Efficacy and safety of rimegepant for the prevention of migraine in Japan: a double-blind, randomized controlled trial. Headache 65:1403\u20131412. https:\/\/doi.org\/10.1111\/head.14995","journal-title":"Headache"},{"key":"2290_CR24","doi-asserted-by":"publisher","first-page":"333102424123294","DOI":"10.1177\/03331024241232944","volume":"44","author":"R Croop","year":"2024","unstructured":"Croop R, Berman G, Kudrow D et al (2024) A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia 44:3331024241232944. https:\/\/doi.org\/10.1177\/03331024241232944","journal-title":"Cephalalgia"},{"key":"2290_CR25","doi-asserted-by":"publisher","unstructured":"Kudrow D, Croop R, Thiry A, Lipton R (2025) A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. Headache Jun 30. https:\/\/doi.org\/10.1111\/head.15002Online ahead of print","DOI":"10.1111\/head.15002"},{"key":"2290_CR26","doi-asserted-by":"publisher","unstructured":"Martin BC, Pathak DS, Sharfman MI et al (2000) Validity and reliability of the migraine-specific quality of life questionnaire (MSQ version 2.1). Headache 40:204\u2013215. https:\/\/doi.org\/10.1046\/j.1526-4610.2000.00030.x","DOI":"10.1046\/j.1526-4610.2000.00030.x"},{"key":"2290_CR27","unstructured":"Mapi Research Trust (2025) Migraine-Specific Quality-of-Life Questionnaire (MSQ Version 2.1), Japanese translation. Available at: https:\/\/eprovide.mapi-trust.org\/instruments\/migraine-specific-quality-of-life-questionnaire#languages. Accessed August 26, 2025"},{"key":"2290_CR28","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1526-4610.2001.01156.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Stewart WF, Sawyer J, Edmeads JG (2001) Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 41:854\u2013861","journal-title":"Headache"},{"key":"2290_CR29","doi-asserted-by":"publisher","unstructured":"Iigaya M, Sakai F, Kolodner KB, Lipton RB, Stewart WF (2003) Reliability and validity of the Japanese Migraine Disability Assessment (MIDAS) Questionnaire. Headache 43:343\u2009\u2013\u200952. https:\/\/doi.org\/10.1046\/j.1526-4610.2003.03069.x","DOI":"10.1046\/j.1526-4610.2003.03069.x"},{"key":"2290_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol group","year":"1990","unstructured":"EuroQol group (1990) EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy 16:199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9","journal-title":"Health Policy"},{"key":"2290_CR31","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jval.2016.03.1834","volume":"19","author":"T Shiroiwa","year":"2016","unstructured":"Shiroiwa T, Ikeda S, Noto S et al (2016) Comparison of value set based on DCE and\/or TTO data: scoring for EQ-5D-5L health states in Japan. Value Health 19:648\u2013654. https:\/\/doi.org\/10.1016\/j.jval.2016.03.1834","journal-title":"Value Health"},{"key":"2290_CR32","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jval.2021.03.010","volume":"24","author":"T Shiroiwa","year":"2021","unstructured":"Shiroiwa T, Noto S, Fukuda T (2021) Japanese population norms of EQ-5D-5L and Health Utilities Index Mark 3: disutility catalog by disease and symptom in community settings. Value Health 24:1193\u20131202. https:\/\/doi.org\/10.1016\/j.jval.2021.03.010","journal-title":"Value Health"},{"key":"2290_CR33","doi-asserted-by":"publisher","first-page":"333102425137168","DOI":"10.1177\/03331024251371686","volume":"45","author":"M Zhang","year":"2025","unstructured":"Zhang M, Guo A, Wu J et al (2025) Rimegepant for the acute treatment of migraine: a phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China. Cephalalgia 45:3331024251371686. https:\/\/doi.org\/10.1177\/03331024251371686","journal-title":"Cephalalgia"},{"key":"2290_CR34","doi-asserted-by":"publisher","first-page":"333102425132060","DOI":"10.1177\/03331024251320608","volume":"45","author":"S Sacco","year":"2025","unstructured":"Sacco S, Ashina M, Diener HC et al (2025) Setting higher standards for migraine prevention: A position statement of the International Headache Society. Cephalalgia 45:3331024251320608. https:\/\/doi.org\/10.1177\/03331024251320608","journal-title":"Cephalalgia"},{"key":"2290_CR35","doi-asserted-by":"publisher","first-page":"333102424126973","DOI":"10.1177\/03331024241269735","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener HC et al (2024) International Headache Society global practice recommendations for preventive Pharmacological treatment of migraine. Cephalalgia 44:3331024241269735. https:\/\/doi.org\/10.1177\/03331024241269735","journal-title":"Cephalalgia"},{"key":"2290_CR36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpain.2014.11.004","volume":"16","author":"DW Dodick","year":"2015","unstructured":"Dodick DW, Turkel CC, DeGryse RE et al (2015) Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. J Pain 16:164\u2013175. https:\/\/doi.org\/10.1016\/j.jpain.2014.11.004","journal-title":"J Pain"},{"key":"2290_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40122-019-0133-1","volume":"8","author":"MJ Doane","year":"2019","unstructured":"Doane MJ, Gupta S, Vo P, Laflamme AK, Fang J (2019) Associations between headache-free days and patient-reported outcomes among migraine patients: a cross-sectional analysis of survey data in Europe. Pain Ther 8:203\u2013216. https:\/\/doi.org\/10.1007\/s40122-019-0133-1","journal-title":"Pain Ther"},{"key":"2290_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1526-4610.2009.01481.x","volume":"50","author":"SD Silberstein","year":"2010","unstructured":"Silberstein SD, Marmura MJ, Shaw J, Yu S (2010) Headache prophylaxis with bonta: patient characteristics. Headache 50:63\u201370. https:\/\/doi.org\/10.1111\/j.1526-4610.2009.01481.x","journal-title":"Headache"},{"key":"2290_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American headache society position statement update. Headache 64:333\u2013341. https:\/\/doi.org\/10.1111\/head.14692","journal-title":"Headache"},{"key":"2290_CR40","doi-asserted-by":"publisher","unstructured":"Croop R, Ivans A, Anderson MS et al (2021) A phase 1 randomized study of hemodynamic effects and Pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. Cephalalgia Rep 4. https:\/\/doi.org\/10.1177\/25158163211007922","DOI":"10.1177\/25158163211007922"},{"key":"2290_CR41","unstructured":"Pfizer (2025) United States Food and Drug Administration. Prescribing Information: NURTEC ODT (rimegepant) orally disintegrating tablets, for sublingual or oral use. Available at: https:\/\/www.fda.gov\/drugsatfda Accessed 12 August 2025"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02290-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02290-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02290-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:21:54Z","timestamp":1772695314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02290-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2290"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02290-6","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki, International Conference on Harmonization guidelines, Good Clinical Practice, and Good Laboratory Practice. All participants provided written informed consent, and these forms and the protocol received Institutional Review Board\/Independent Ethics Committee approval prior to initiation of the study. The list of Institutional Review Boards\/Independent Ethics Committees for this study was reported previously [\n                      \n                      ].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YM received personal consultancy fees from Amgen Astellas BioPharma K.K., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K. and Otsuka Pharmaceutical Co., Ltd. and research grants from Pfizer Japan Inc., AbbVie GK, Eli Lilly Japan K.K., Amgen K.K, during the conduct of the study. SK is a consultant for Eli Lilly Japan K.K, and reports lecture fees from Eli Lilly Japan K.K., Daiichi Sankyo Company, Limited, and Otsuka Pharmaceutical Co., Ltd. TY reports no conflicts of interest. TI is an employee of Pfizer and owns stock\/options in Pfizer. YH is an employee of Pfizer and owns stock\/options in Pfizer. HY is an employee of Pfizer and owns stock\/options in Pfizer. AT was an employee of Biohaven Pharmaceuticals, owns stock in Biohaven Ltd, is an employee of Pfizer, and owns stock\/options in Pfizer. AA is an employee of Pfizer and owns stock\/options in Pfizer. TF is an employee of Pfizer and owns stock\/options in Pfizer. FS is a consultant for Amgen, Otsuka, and Eli Lilly. TT is an advisor for Sawai, Teijin, and Hedgcock MedTech; and reports honoraria (Otsuka, Amgen, Eli Lilly Japan, and Daiichi-Sankyo) and grants for commissioned\/joint research (Pfizer, Lundbeck, AbbVie, Eli Lilly Japan).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}